freeze-dried powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
=== Clinical attachment level === The clinical attachment level (CAL) combines the measurements of probing pocket depth and any gingival recession to give an overall indication of where the periodontal tissues attach to the root surface. It is measured from a constant reference point, usually the CEJ, to the base of the periodontal pocket. Due to the more stable and reproducible property, this is considered the best measure of changes in residual periodontal support over time.
The 2013 Cochrane Collaboration review (updated in 2026) on physical exercise for depression noted that, based upon limited evidence, it is moderately more effective than a control intervention and comparable to psychological or antidepressant drug therapies. Smaller effects were seen in more methodologically rigorous studies. Three subsequent 2014 systematic reviews that included the Cochrane review in their analysis concluded with similar findings: one indicated that physical exercise is effective as an adjunct treatment with antidepressant medication; the other two indicated that physical exercise has marked antidepressant effects and recommended the inclusion of physical activity as an adjunct treatment for mild–moderate depression and mental illness in general. These studies also found smaller effect sizes in more methodologically rigorous studies. All four systematic reviews called for more research in order to determine the efficacy or optimal exercise intensity, duration, and modality. A 2025 systematic review on the effectiveness of rock climbing for depression reported that indoor bouldering combined with mindfulness exercises may be an effective, clinically meaningful, safe, and sustainable adjunctive intervention for adults with moderate depression. However, the review found insufficient data to determine whether it was superior to other established treatments.
The CMP continued in later years to replace some of Guimard's designs with more sober entrances by Cassien-Bernard, often a plain balustrade in white stone, for example at Gare de l'Est, Madeleine, Montparnasse, and Saint-François-Xavier. Modernization beginning after World War I also led to the demolition of many, especially the more elaborate. Shortly before World War II, it was suggested that those remaining should be scrapped for their metal. Art Nouveau had only briefly been in fashion and only became popular once more in the last quarter of the 20th century.
Nuclear Magnetic Resonance (NMR) was invented in the 1940s and 1950s to study physical systems. In the 1970s, several research groups started to use NMR to study biological tissues. Such studies provided the biophysical basis for the development of Magnetic Resonance Imaging (MRI). MRI is based on imaging the relaxation times (or spin diffusion coefficients D) of water protons in biological tissues. Namely, the image contrast in MRI is based on relaxation times (or spin diffusion) differences instead of differences in spin density. The development of MRI for cancer detection involved three major milestones during the period of 1970–1973: (1) The study of Carlton Hazlewood and Donald Chang (Baylor College of Medicine and Rice University, 1969–1972): Using rat skeletal muscle and mouse mammary glands, they demonstrated that the NMR relaxation times T1 and T2 differ between cellular water and bulk water. Furthermore, they found that these relaxation times depend directly on the tissue's physiological state. Their findings suggested that NMR can be used to detect cancer. Indeed, using a mouse model of mammary tumor, they showed that T1, T2 and D (spin diffusion coefficient) change progressively during tumor development. An American Physical Society (APS) press release in 1972 highlighted their discovery, which suggested that early development of cancer could be detected using NMR.
=== United Kingdom === Rhodesia was originally a self-governing British crown colony. Although decolonisation in Africa had begun after World War II, it began accelerating in the early 1960s, causing Britain to negotiate independence rapidly with several of its colonies. During this period, it adopted a foreign policy called NIBMAR, or No Independence Before Majority African Rule, mandating democratic reforms that placed governance in the hands of the majority black Africans. The governing white minority of Rhodesia, led by Ian Smith, opposed the policy and its implications. On 11 November 1965, Rhodesia's minority white government made a unilateral declaration of independence (UDI) from the United Kingdom, as it became apparent that negotiations would not lead to independence under the white regime. The United Kingdom government immediately brought in legislation (Southern Rhodesia Act 1965) which formally abolished all Rhodesian government institutions. This move made life difficult for Rhodesian citizens who wished to travel internationally as passports issued by Rhodesia's UDI administration were not recognised as valid; in January 1966, the British issued a statement accepting as valid any passport issued before the declaration of independence and allowing six-month United Kingdom passports to be granted when they expired – provided that the bearer declared they did not intend to aid the UDI Rhodesian government.
Sources: en.wikipedia.org
== Other == Lower levels of adiponectin are associated with ADHD in adults. Adiponectin levels were found to be increased in rheumatoid arthritis patients responding to DMARDs or TNF inhibitor therapy. A low adiponectin to leptin ratio has been found in patients with COVID-19 pneumonia compared to healthy controls. Exercise induced release of adiponectin increased hippocampal growth and led to antidepressive symptoms in mice. Several studies have found a positive correlation in caffeine consumption and increased adiponectin levels, although the mechanism for this is unknown and requires more research.
=== Other conditions === LSD has been studied for the relief of pain and headaches. It has been used as a treatment for cluster headaches with positive results in some small studies. The drug might have analgesic properties related to pain in terminally ill patients and phantom pain and might be useful for treating inflammatory diseases such as rheumatoid arthritis due to anti-inflammatory effects.
==== Ribo-seq/Ribosome profiling/Ribosome footprinting ==== In Ribosome profiling, cellular mRNA including, polysomes, is subjected to ribonucleases, enzymes that cleave RNA. Those positions in the RNA molecules that are bound by ribosomes are protected against digestion. After cessation of ribonuclease activity, these protected sites can be recovered and sequenced. The sequences obtained from ribo-seq, therefore, represent fragments of mRNAs that were being actively translated.
Food Stories Archived 10 April 2021 at the Wayback Machine – Explore a century of revolutionary change in UK food culture on the British Library's Food Stories website Groceteria – supermarket history and architecture from the 1920s to the 1970s Scrambling for customers, 4 August 2005, San Francisco Chronicle
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.